Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages

  Haase, Christiane L ^a   Tybjærg Hansen, Anne ^a,b   Grande, Peer ^a   Frikke Schmidt, Ruth ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650052979     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0450     Document Type: Article

References (40)

1. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R 2007 Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 370:1829-1839
2. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A 2008 Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:2524-2532 (Pubitemid 351787208)
3. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E 2001 High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033
4. Cuchel M, Rader DJ 2006 Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113: 2548-2555
5. Tall AR, Breslow JL, Rubin EM 2001 Genetic disorders affecting plasma high-density lipoproteins. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2915-2936
6. Sorci-Thomas MG, Thomas MJ 2002 The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12:121-128
7. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF 1996 Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Atherosclerosis 127:255-262
8. Wang XL, Badenhop R, Humphrey KE, Wilcken DE 1996 New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol 13:1-10
9. Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, Schaefer EJ 2002 Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet 61:176-184
10. Brown CM, Rea TJ, Hamon SC, Hixson JE, Boerwinkle E, Clark AG, Sing CF 2006 The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. J Mol Med 84:561-572 (Pubitemid 43992848)
11. Boekholdt SM, Souverein OW, Tanck MW, Hovingh GK, Kuivenhoven JA, Peters RI, Jansen H, Schiffers PM, van der Wall EE, Doevendans PA, Reitsma PH, Zwinderman AH, Kastelein JJ, Jukema JW 2006 Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clin Genet 69:263-270
12. Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE 1990 Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 31:1371-1377
13. Morcillo S, Cardona F, Rojo-Martínez G, Esteva I, Ruíz-de-Adana MS, Tinahones F, Gómez-Zumaquero JM, Soriguer F 2005 Association between MspI polymorphism of the APO AI gene and type 2 diabetes mellitus. Diabet Med 22:782-788
14. Do HQ, Nazih H, Luc G, Arveiler D, Ferrières J, Evans A, Amouyel P, Cambien F, Ducimetière P, Bard JM 2009 Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on highdensity lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism 58:283-289
15. Peacock RE, Hamsten A, Johansson J, Nilsson-Ehle P, Humphries SE 1994 Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein Band lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses. Clin Genet 46:273-282
16. Wang XL, Liu SX, McCredie RM, Wilcken DEL 1996 Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 98:372-377 (Pubitemid 26255736)
17. Reguero JR, Cubero GI, Batalla A, Alvarez V, Hevia S, Cortina A, Coto E 1998 Apolipoprotein A1 gene polymorphisms and risk of early coronary disease. Cardiology 90:231-235
18. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE 1993 Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 100:157-169
19. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG 2002 Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. Eur Heart J 23:620-626
20. Julian DG, Bertrand ME, Hjalmarson Å, Fox K, Simoons ML 1997 Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 18:394-413
21. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
22. Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, Tybjaerg-Hansen A, Nordestgaard BG 2009 Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab 94:1264-1273
23. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG 2008 Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897-1908
24. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R 1999 Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341-353
25. Fullerton SM, Buchanan AV, Sonpar VA, Taylor SL, Smith JD, Carlson CS, Salomaa V, Stengård JH, Boerwinkle E, Clark AG, Nickerson DA, Weiss KM 2004 The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. Hum Genet 115:36-56
26. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, Eckardstein A, Assmann G 1996 Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 94:1622-1628
27. Recalde D, Velez-Carrasco W, Civeira F, Cenarro A, Gomez-Coronado D, Ordovas JM, Pocovi M 2001 Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo AIZaragoza (L144R). Atherosclerosis 154:613-623
28. Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D 2001 Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol 12:181-207
29. Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI 2004 Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry 43:2126-2139
30. Shioji K, Mannami T, Kokubo Y, Goto Y, Nonogi H, Iwai N 2004 An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese. J Hum Genet 49:433-439
31. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH 2004 Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869-872
32. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE 1999 Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 82:235-241
33. Zhang X, Chen ZQ, Wang Z, Mohan W, Tam SP 1996 Protein- DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene. J Biol Chem 271:27152-27160
34. Tuteja R, Tuteja N, Melo C, Casari G, Baralle FE 1992 Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition. FEBS Lett 304:98-101
35. Angotti E, Mele E, Costanzo F, Avvedimento EV 1994 A polymorphism (G→A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency. J Biol Chem 269: 17371-17374
36. Danek GM, Valenti M, Baralle FE, Romano M 1998 The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency. Biochim Biophys Acta 1398:67-74
37. Hokanson JE, Cheng S, Snell-Bergeon JK, Fijal BA, Grow MA, Hung C, Erlich HA, Ehrlich J, Eckel RH, Rewers M 2002 A common promoter polymorphism in the hepatic lipase gene (LIPC-480C3T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 51:1208-1213
38. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B 2007 Effects of torcetrapib in patients at high risk for coronary events. N Eng J Med 357:2109-2122
39. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR 2008 Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161-169
40. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308